The evolving role of BTK inhibitors in multiple sclerosis
This episode of the VJNeurology podcast explores the evolving role of Bruton’s tyrosine kinase (BTK) inhibitors in the treatment of multiple sclerosis (MS), from the role of BTK in MS pathophysiology to the recent EU approval of tolebrutinib for secondary progressive MS without relapses. Experts discuss the pivotal Phase III HERCULES (NCT04411641) and GEMINI (NCT04410978) trial data supporting tolebrutinib, alongside findings from the Phase III FENtrepid trial (NCT04544449) of fenebrutinib, a non-covalent BTK inhibitor, in primary progressive MS.
Featuring Augusto Miravalle, MD, FAAN, Rush…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.